"BIOLOGICAL" DRUGS PERHAPS UNDER DEVELOPMENT
THAT MIGHT BE EFFECTIVE FOR  AUTOIMMUNE VASCULITIDES

(Last Update 2 August 2008)

This table was compiled over several years, beginning in about 1995 by a vasculitis patient with NO medical training.  Very likely many of the listed developments have been dropped as most drugs in development don't get approved.

The meds listed here are ones that have only a rather limited chance of being useful to treat autoimmune vasculitides, but in most cases, that's not the intended use.  Perhaps the one's with the most promising aspect are the several CTLA-4 possibilities and the BLYS developments.  Any medications that selectively inhibit activation of the B cells may be useful as experience with Rituxan has shown.

Anyone interested in pursuing an interest should contact the supposed developer.



DRUG
MANUFACTURER

   Abatacept  (CTLA-4-Ig) for autoimmune  diseases

     Bristol-Myers Squibb  (App'd for severe R.A. by FDA)

   RG2077 (CTLA4-Ig)                             (2005)
      Repligen                  (Phase I for MS and Lupus)
   Arcalyst (rilonacept, anti-IL-1) for selected AI diseases
      Regeneron Pharmaceuticals (Fast tracked)

  Anti-TNF (anti-Tumor Necrosis Factor) Drugs:
 
    CDP870 (PEGylated humanized Fab fragment-
                      anti-TNF)
    ISIS 104838   (An anti-sense TNF-alpha inhibitor)
    PEG-sTNFrl  (PEGylated humanized soluble TNF
                              receptor)

    CENTO 148   (Human anti-TNF Mab)        
    TACE Inhibitor (TNF-alpha converting    
                                  enzyme inhibitor
    AME-527        (Fully human anti-TNF Mab)

   
   
    Celltech                           (Ph. III for R.A.)
     

    ISIS Laboratories          (Ph. II for R.A.)
    AMGEN
 

     Centocor                           (Ph I for R.A.)
    Briston-Myers Squibb   (Ph. II for R.A.)
  


        Applied Molecular Evolution, Inc.  (Ph I/II for R.A.)

  ABT874          (Human anti-IL 12)

   Abbot Laboratories          (Phase II for R.A./Crohn's)

  CAT192    (Human anti-TGF? monoclonal AB)

  Cellcept                                (For systemic sclerosis)
  Epratumzamab (Anti-CD-22)
   Immunomedics                   (Unpecified autoimmune diseases)

  Kineret     (Anakinra, Anti-IL-1ra monoclonal
                     antibody)

  Amgen                                   (Approved for R.A.)
  HuMax  ( Ofatumumab, Human anti-IL-15 Mab)       
  Genmab/Amgen/Medarex (Phase II for R.A.)
  Pralnacasan (Small molecule                  
    interleukine-1 converting enzyme [ICE] inhibitor)
 		  Vertex                                     (Phase II for RA)
  VX-740     (Small molecule interleuking-1 
                     converting enzyme [ICE] inhibitor)
  Aventis                                   (Phase II for R.A.)
  IL-1 Trap   (IL-1 receptor fusion protein     
  Regeneron                            (Phase II for R.A.)
  sIL-1r2      (Soluble IL-1 receptor type II)  
   Amgen                                  (Phase I for R.A.)
  MRA  (Humanized anti-IL-6 receptor Mab)   
  Chugai                                   (Phase II for R.A.)

  CD4 antibody

  TolerRxInc

  CD18 antibody (LDP-01)

  LeukoSite, Inc.     (affects white cell adhesion)

  Aglycosyl CD3 antibody (modified OKT-3)

  Therapeutic Antibody Center
   HuMax-CD20     (Targets B cells)             
 
   Gemmab  (Preclinical development for
                        various autoimmune diseases)
  AME-133 (Anti-CD 20, B cell suppressant)       Applied Molecular Evolution, Inc. (Preclinical)

  Raptiva  (Efalizumab, anti-CD11a)              

  Genentech and XOMA  (Ph. III for Psoriasis, not R.A.)

  Amevive (Alefacept, targets                      
                    selected T-cells) 

  Biogen                    (Chronic Plaque Psoriasis)

  Antegren  (Natalizumab  Alpha-4     WITHDRAWN
                     Integrin Inhibitor)

  Elan Corporation, plc and Biogen, Inc. (Ph II for
             (Humanized monoclonal AB)        Crohn's and MS)
  SCIO-469   (Inhibits p38 kinase TNF-alpha, IL-1,
  SCIO-323   and  (COX-2)                            
  SCIOS   (May be acquired by Johnson &
                  Johnson; SCIO-323 is 2nd Generation)
  VX-702      (p38 MAP kinase inhibitor              VERTEX                                 (Phase II for R.A.)
  681323      (p38 MAP kinase inhibitor)        
   GlaxoSmithKline                  (Phase I for R.A.)
  BIRB796  (p38 MAP kinase inhibitor)         
   Boehringer Ingelheim         (Phase II for R.A.)
  LymphoStat-B (Belimumab;anti-BLyS, one of the BAFFs,   
      fully-human IgG1-λ monoclonal antibody)
  Human Genome Sciences  (Phase II for SLE)
  TACI-Ig   (Inhibits BLyS & APRIL)                       ZymoGenetics and Serono  (Phase I in U.K.)
  Eculizumab (Inhibits C5 complement)          Alexion Pharmaceuticals, Inc. (Phase III for RA)
  Bexxar            (Anti-CD20)                              GlaxoSmithKline             (Approved for NH lymphoma)
  BG9588          (Anti-CD40L)                            BioGen                               (SLE, possibly other AI)
  TKB662   (Inhibits activation and              
                     proliferation of T & B cells)
   Isotecknika, Inc.               (Experimental, psoriasis
                                                 steroid sparing)
  ISA247     (Calcineurin inhibitor)                
  Isotecknika, Inc.                (Phase III for psoriasis)
  CP-690,550  (Inhibits enzyme JAK3 in immune cells)
   Pfizer                                   (Not ready for human use)
  PLX647  (dual c-Kit and FMS kinase inhibitor)   Plexxikon                            (Pre-clinical for psoriasis)
  Riquent® (Abetimus sodium)                     
  La Jolla Pharmaceutical Co. (Phase III for lupus)
  AK216348 (Selective glucocorticoid receptor agonists (SEGRA)   Experimental
  NCX-1015 (Nitrosteroid,appears to not active osteoclasts)   Experimental
  IMATINIB (Anti-IL-5, Gleevec (USA) or Glivec (Europe/Australia)
   Novartis Pharmaceuticals  (FDA approved for
                                                      chronic  myelogenous leukemia)
  Mepolizumab (Anti-IL-5 for hypereosinophilia)
    SmithKlineBeecham U.K.  (Phase i for Hypereosinophilic Syndromes)
                                                     (Phase II for Eosinophilic Gastroenteritis,
                                                       Churg-Strauss Syndrome,
                                                       Eosinophilic Esophagitis
  HuMax (Ofatumumab, Anti-CD20)
    Genmab (GlaxoSmithKline)       (Phase III for RA and NHL)
  TRU-015 (Anti-CD20)
    Trubion Pharmaceuticals   (Phase I for RA)
  Ocrelizumab (humanized anti CD20)    Genentech                              (Phase III for RA, SLE, lupus nephritis
phase II for relapsing MS)
  Tocilizumab [Actemra] (humanized anti IL-6 receptor antibody)
    Roche and Chugai
  Veltuzumab (humanized anti-CD20 for sub-cutaneous injection)
    Immunomedics-Nycomed  In development for autoimmune diseases
                                                      Ph 1/2 for ITP to start
<>   SGN-70 (anti-CD70)    Seattle Genetics                    (Phase I for autoimmune lymphocytic diseases)

      # It is known by several other names including HAT (Humanized Anti-Tac),  SMART anti-Tac, and humanized
         anti-IL2-receptor.

See also http://www.bitsplace.com/bitsplace/Autoimmunediscomp.html

The following table is from a September 2007 article at http://en.wikipedia.org/wiki/Certolizumab_pegol